Bigfoot Biomedical Archives - Medical Design Sourcing

The 10 biggest diabetes tech stories from 2023

Medtronic, EOFlow, Dexcom, Beta Bionics and Tandem Diabetes Care all contributed some of the biggest diabetes technology stories of 2023.

It was another banner year for diabetes technology, with regulatory approvals, product launches and M&A all playing their part.

Diabetes technology’s impressive 12 months marked a major trend across medtech as a whole, too.

In 2022, the diabetes space saw plenty of progress from some of its biggest names and this past year proved no different. Big hitters like Dexcom, Abbott, Medtronic, Insulet and more all contributed to some of the biggest stories in 2023. External factors — like popular GLP-1 drugs and big tech names looking to enter the space — also made the cut.

Here are 10 of the most intriguing diabetes technology stories from the past 12 months.

Medtronic was set to buy EOFlow — until it wasn’t

The medtech giant made a big splash in the insulin delivery space when it announced its plan to buy South K…

Abbott completes Bigfoot Biomedical acquisition

The Bigfoot Unity platform, now acquired by Abbott. [Image courtesy of Bigfoot Biomedical]Abbott (NYSE:ABT) announced today that it completed its previously announced acquisition of Bigfoot Biomedical.

Pursuant to the terms of the merger agreement, upon completion, Bigfoot became a wholly-owned subsidiary of Abbott. The companies declined to disclose financial terms.

Abbott announced on Sept. 5 that it entered into a definitive agreement to acquire the smart insulin management company. Their longstanding relationship dates back to 2017, with the medtech giant even leading a financing round for Bigfoot in 2020.

Get the full story at our sister site, Drug Delivery Business News.

Abbott to acquire insulin management company Bigfoot Biomedical

The Bigfoot Unity platform, now acquired by Abbott. [Image courtesy of Bigfoot Biomedical]Abbott (NYSE:ABT) announced today that it entered into a definitive agreement to acquire smart insulin management company Bigfoot Biomedical.

The transaction remains subject to customary closing conditions and the companies declined to disclose financial terms. They expect it to close in the third quarter of 2023.

Abbott has a longstanding relationship with Bigfoot going back to 2017. The medtech giant even led a financing round for the company back in 2020.

Bigfoot develops the Bigfoot Unity smart insulin management system. The FDA-cleared Bigfoot Unity platform aims to simplify continuous glucose monitors (CGMs) and the data they produce. It features a smart insulin pen cap, which takes data from a CGM and informs the patient exactly how much insulin they need.

Get the full story at our sister site, Drug Delivery Business News.

The biggest stories from the American Diabetes Association (ADA) 2023 Scientific Sessions

From left: the Insulet Omnipod 5, Medtronic MiniMed 780G and the Senseonics Eversense E3. These technologies were part of some of the biggest stories from the American Diabetes Associations’ 2023 Scientific Sessions. [Images courtesy of Insulet, Medtronic and Senseonics]As it does every year, this past week, the American Diabetes Association convened its Scientific Sessions to bring together leaders in the diabetes space.

At last year’s event, next-generation technologies from the big hitters took the spotlight. The 83rd iteration this past week produced a range of new studies, product updates and positive news for a range of technologies and innovations. From continuous glucose monitors (CGMs) to insulin pumps to digital platforms and diabetes reversal procedures, ADA 2023 saw it all.

Usual suspects, like Dexcom, Abbott, Medtronic and Insulet shared their updates. Meanwhile, promising data came out of Senseonics, Sernova, Bigfoot Biomedical and more.<…

Real-world data supports Bigfoot Biomedical diabetes management platform

The Bigfoot Unity platform. [Image courtesy of Bigfoot Biomedical]Bigfoot Biomedical today announced study data demonstrating the potential of its Bigfoot Unity system for diabetes management.

The FDA-cleared Bigfoot Unity platform aims to simplify continuous glucose monitors (CGMs) and the data they produce. It features a smart insulin pen cap, which takes data from a CGM and informs the patient exactly how much insulin they need.

Milpitas, California-based Bigfoot Biomedical published the six-month retrospective analysis in the American Diabetes Association’s (ADA) journal, Clinical Diabetes. Dr. Bantwal Baliga, East Alabama Endocrinology, served as lead author of the manuscript.

In an initial real-world, 58-person cohort, results highlight Bigfoot Unity’s ability to support rapid and durable improvement in glucose control. It evaluated the system in people with diabetes who use multiple daily injections of insulin.

Bigfoot Biomedical takes next steps for its holistic diabetes management platform

The Bigfoot Unity platform. [Image courtesy of Bigfoot Biomedical] After executing a significant IP sale, Bigfoot Biomedical looks to double down on its diabetes management platform.

Less than two years ago, Bigfoot Biomedical launched its Bigfoot Unity platform in some U.S. states. CEO Jeffrey Brewer last year called it a “transformational attempt” to simplify CGMs and the data they produce. It features a smart insulin pen cap, which takes data from a CGM and informs the patient exactly how much insulin they need.

Just last month, the company made a major play to further bolster this platform. It sold pump-based automated insulin delivery technology patents to pump maker Insulet for $25 million. This asset sale generated significant funds to expand the Bigfoot Unity diabetes management system.

Further positives followed within weeks, as Bigfoot soon after received FDA clearance for the Android mobile app for Bigfoot Unity. The mobile app allows users to input …

Bigfoot Biomedical wins FDA clearance for Bigfoot Unity Android app

The Bigfoot Unity platform. [Image courtesy of Bigfoot Biomedical]Bigfoot Biomedical announced today that it received FDA 510(k) clearance for the Android version of its Bigfoot Unity mobile app.

The Milpitas, California-based company received FDA clearance for its diabetes management platform in May 2021. Its initial rollout featured compatibility with iOS devices. The first-of-its-kind system includes connected smart pen caps designed to recommend insulin doses for diabetes patients using multiple daily injection (MDI) therapy.

Bigfoot’s smart pen caps offer on-demand insulin dose decision support. This helps to minimize guesswork and help patients to follow their doctors’ instructions. Additionally, the caps have compatibility with a broad range of disposable insulin pens for both long-acting and rapid-acting insulin.

Get the full story at our sister site, Drug Delivery Business News.

Insulet acquires insulin pump patents from Bigfoot Biomedical for $25M

Insulet (Nasdaq:PODD) announced today that it acquired assets related to Bigfoot Biomedical’s pump-based automated insulin delivery technologies.

Acton, Massachusetts-based Insulet paid $25 million to acquire the AID assets. These include certain Bigfoot patents related to pumps that may be used for AID therapy. Insulet already develops its own AID technology with its Omnipod platform.

Get the full story at our sister site, Drug Delivery Business News.

6 drug delivery innovations you need to know

From wearable insulin delivery devices to drug-eluting implants and everything in between, drug delivery innovation never stops.

Vaccines, life-saving therapeutics, vision-correcting drugs and more are being developed and marketed for delivery with all kinds of technologies.

More than a year ago, we compiled a list of eight drug delivery innovations you need to know. With some updates on some of those technologies, plus introductions to others, here are some more impressive developments you should keep an eye on:

1. Needle-free delivery

Vaccines have become a major talking point over the past couple of years amid the COVID-19 pandemic and a number of companies are working on ways to deliver them, as well as other forms of medication, through different avenues.

A major speed bump in vaccine hesitancy can be fear of needles, so the introduction of needle-free drug delivery could make big waves in the space.

Two companies pushing forward with …

The biggest stories from the American Diabetes Association (ADA) 2022 Scientific Sessions

For the 82nd time, the American Diabetes Association (ADA) Scientific Sessions convened to highlight all the innovations within the diabetes technology space.

Major players like Dexcom, Medtronic, Abbott and more continue to plug along, while companies like Bigfoot Biomedical, One Drop and others shared data backing the technology that they bring to the table.

The data showcased at ADA supported the usual continuous glucose monitoring (CGM) and automated insulin delivery (AID) technology, plus different digital health platforms and diabetes reversal procedures.

BTIG analyst Marie Thibault wrote in a report that there was plenty of buzz on the ground at the event, particularly around Insulet’s Omnipod 5 AID system, Abbott’s recently FDA-cleared FreeStyle Libre 3 CGM and Bigfoot Biomedical’s Bigfoot Unity platform.

“In general, we believe that accuracy and clinical benefit is proven for all commercial CGM and AID offerings an…

Bigfoot Biomedical’s Bigfoot Unity demonstrates strong glycemic control in Type 2 diabetes

Bigfoot Biomedical’s Bigfoot Unity platform. [Image from Bigfoot Biomedical]Bigfoot Biomedical announced data supporting the use of its Bigfoot Unity system for improving glycemic control in those with diabetes.

Data from a real-world retrospective analysis suggests that, for those on multiple daily injections (MDI) of insulin, Bigfoot Unity has the potential to provide rapid and durable glycemic control improvements.

Milpitas, California-based Bigfoot presented the real-world data from its late-breaking abstract at the American Diabetes Association (ADA) 82nd Annual Scientific Sessions in New Orleans.

Get the full story at our sister site, Drug Delivery Business News.

Bigfoot Biomedical adds former Insulet VP as chief commercial officer

Bigfoot Biomedical’s smart insulin pen cap [Image from Bigfoot Biomedical]Bigfoot Biomedical announced today that it appointed former Insulet executive Matt Rainville as its chief commercial officer.

Rainville’s role includes leading the growth of Milpitas, California-based Bigfoot Biomedical’s fully commercial Bigfoot Unity diabetes management program as the company looks to expand access to its offerings.

Get the full story at our sister site, Drug Delivery Business News.